Industry News
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, California. This is a first-in-human trial targeting the tumor-associated form of MUC1, called MUC1* (muk 1 star). MUC1* is the transmembrane cleavage product that is a growth…
Read More
Excerpt from the Press Release: Atara Biotherapeutics, a California-based developer of cell therapies, will sell a large factory it built there to a contract manufacturing division of Japan’s Fujifilm, announcing Wednesday a $100 million deal with Fujifilm Diosynth Biotechnologies. The facility, which encompasses 90,000 square feet in Thousand Oaks, California, was once a key component of Atara’s…
Read More
– Israel Institute for Biological Research files initial scientific results of BriLife vaccine effectiveness in producing neutralizing antibody against Omicron Variant – Neutralizing antibody level against Omicron is approximately 1/3 of the comparable antibody level against the original Corona Virus – Ten of 13 tested patients vaccinated during phase 2 trials demonstrated measurable level of…
Read More
Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies Excerpt from the Press Release: SAN DIEGO, Jan. 26, 2022 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on developing targeted protein degraders to create life-saving medicines, today announced dosing of the first patient in a new, first-in…
Read More
– If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone -Initial Phase 1/2 data readout anticipated in the second half of 2022 -BridgeBio’s gene therapy portfolio also includes a clinical stage…
Read More
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIV First-in-human trial is now open for enrollment Excerpt from the Press Release: SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced…
Read More
Funding from the Bill & Melinda Gates Foundation will support the development of Aridis’ inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19 Excerpt from the Press Release: OS GATOS, Calif., Jan. 27, 2022 /PRNewswire/ — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat…
Read More
Enrollment in the first dose escalation is complete with no safety issues reported to date Trial is designed to accelerate pelareorep’s development in Asian territories such as China, the world’s second-largest pharmaceutical market Excerpt from the Press Release: SAN DIEGO, Calif. and CALGARY, AB, Jan. 27, 2022 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye…
Read More
Excerpt from the Press Release: Study met primary endpoint with 47.4% objective response rate Safety and tolerability profile consistent with previously reported data Planned BLA submission on track for later this year Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) — Checkpoint…
Read More
Excerpt from the Press Release: STI-1558, a novel oral Mpro inhibitor, effectively inhibits Omicron virus entry and replication in cells. STI-1558 is orally bioavailable with improved human liver microsomal stability to avoid using Ritonavir as a pharmacokinetic enhancer in humans. SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today…
Read More